---
title: "Assessment of the impairment of the serotoninergic system during the prodromal phase of Parkinson’s disease in SNCA mutation carriers by PET using [11C]DASB and [11C]SB207145 : SerIAL-PD"
euct_id: 2024-516610-38-00
status: Not yet recruiting
sponsor: Institut National De La Sante Et De La Recherche Medicale
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-516610-38-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-516610-38-00"
ctis_last_updated: "2026-02-11T02:33:48.243474704"
source: EU Clinical Trials Information System (CTIS)
---
# Assessment of the impairment of the serotoninergic system during the prodromal phase of Parkinson’s disease in SNCA mutation carriers by PET using [11C]DASB and [11C]SB207145 : SerIAL-PD

**EU CT Number:** [2024-516610-38-00](https://euclinicaltrials.eu/ctis-public/view/2024-516610-38-00)

## Key Facts

- **Status:** Not yet recruiting
- **Sponsor:** Institut National De La Sante Et De La Recherche Medicale
- **Start Date:** 2025-09-01
- **Completion Date:** 2029-03-01
- **Conditions:** Parkinson's disease, Prodromal phase of Parkinson's disease, Disease prodromal stage
- **Interventions:** 11C-SB207145, 11C-DASB

## Member States

Trial is authorized in 1 member state: France.

## Sites (2)

- CERMEP - imagerie du vivant, BRON cedex, France
- APHP - Hôpital Universitaire Pitié-Salpêtrière, PARIS, France

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's disease; Prodromal phase of Parkinson's disease; Disease prodromal stage
Age groups: elderly 65+, adults 18-64
Sex: male, female
Includes a vulnerable population.
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-516610-38-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-516610-38-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-516610-38-00*